Dishman Carbogen Amcis vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Dishman Carbogen Amcis (DCAL) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 13, 2026.
As of Aug 13, 2026, Fair Value Calculator sees Dishman Carbogen Amcis as the less overvalued of the two: Dishman Carbogen Amcis trades at ₹191 versus a fair value of ₹109 (-43%), while Vertex Pharmaceuticals trades at $530 versus $279 (-47%).
Dishman Carbogen Amcis
DCAL.NSE · INR · Health Care
-43%
upside to fair value
overvalued
Price₹191
Fair Value₹109
Quality45/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-47%
upside to fair value
overvalued
Price$530
Fair Value$279
Quality79/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Dishman Carbogen AmcisVertex Pharmaceuticals
Valuation
27.4×P/E (TTM)28.8×
0.91×P/S (TTM)10.06×
0.40×P/B6.59×
5.7×EV/EBITDA23.8×
—PEG1.72×
Profitability
3%Net margin36%
9%Operating margin38%
2%Return on equity24%
1%Return on assets12%
Growth
19%Revenue growth (YoY)8%
8.2%Avg. growth/yr (3Y)10.6%
8.9%Avg. growth/yr (5Y)14.2%
Balance & size
0.23×Debt / equity0.03×
$281MMarket cap$123B
healthyGrowth qualityhealthy
Vertex Pharmaceuticals leads: 5 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Dishman Carbogen Amcisof which business quality 44 · market factors 33Vertex Pharmaceuticalsof which business quality 77 · market factors 78
ProfitabilityMargins and returns on capital today
17
72
Quality GrowthAre margins and returns improving?
41
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
66
58
Low VolatilityCalm price path (market factor)
53
86
MomentumPrice trend over the last 3–12 months (market factor)
27
68
52W MomentumDistance to the 52-week high (market factor)
21
86
Net IssuanceBuybacks instead of dilution
74
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Dishman Carbogen Amcis
DCF Models₹133
Earnings-Based₹79.78
Dividend Discount₹3.63
Multiples₹144
Asset-Based₹285
Growth DCF₹104
Economic Profit₹190
Growth Earnings₹101
20 of 26 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
21 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Dishman Carbogen Amcis
Bear ₹79.25Fair Value ₹109Bull ₹169
₹191 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$530 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Dishman Carbogen Amcis · Health Care
Quality score45 · below median
Fair value upside-43% · below median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-47% · below median
Bottom line
As of Aug 13, 2026, Fair Value Calculator sees Dishman Carbogen Amcis as the less overvalued of the two: Dishman Carbogen Amcis trades at ₹191 versus a fair value of ₹109 (-43%), while Vertex Pharmaceuticals trades at $530 versus $279 (-47%).
Vertex Pharmaceuticals has the higher quality score (79/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
